Niraparib Maintenance Does Not Produce Long-term OS Benefit in Recurrent Ovarian Cancer
Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.
United States Dana Farber Cancer Institute Ursula Matulonis Society Of Gynecologic Oncology Division Of Gynecologic Oncology Society Of Gynecological Oncology
Source: onclive.com